Related Experiment Video
Updated: Sep 18, 2025
Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages
Published on: June 23, 2013
Swertianin Suppresses M1 Macrophage Polarization and Inflammation in Metabolic Dysfunction-Associated Fatty Liver
Jing Xia1,2, Wei Xiong1,2, Ce Yang1,3
1Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing 404120, China.
Abstract:
Background: Metabolic dysfunction-associated fatty liver disease (MASLD) is closely associated with immune dysregulation and macrophage-driven inflammation. The activation of PPARG plays a critical role in modulating macrophage polarization and lipid metabolism, suggesting its potential as a therapeutic target for MASLD. Methods: We used UPLC-Q/TOF-MS and network pharmacology to investigate the key components and targets of Swertia davidi Franch, focusing on Swertianin. In vitro experiments on macrophages were conducted to assess the modulation of M1 polarization, and a mouse model of MASLD was utilized to explore the therapeutic effects of Swertianin. Results: Swertianin activated PPARG, leading to significant inhibition of M1 macrophage polarization, a reduction in lipid accumulation, and decreased inflammatory marker levels both in vitro and in vivo. The treatment significantly improved liver pathology in mice, indicating its therapeutic potential for MASLD. Conclusions: Swertianin's activation of PPARG provides a novel mechanism for treating MASLD, targeting both macrophage polarization and inflammation.
Insights
Swertianin effectively treats metabolic dysfunction-associated fatty liver disease (MASLD) by activating PPARG. This action reduces macrophage inflammation and lipid accumulation, improving liver health.
Area of Science:
- Pharmacology
- Hepatology
- Immunology
Background:
- Metabolic dysfunction-associated fatty liver disease (MASLD) involves immune dysregulation and macrophage inflammation.
- PPARG activation is crucial for macrophage polarization and lipid metabolism in MASLD.
- PPARG represents a potential therapeutic target for MASLD.
Purpose of the Study:
- To investigate Swertia davidi Franch components and targets using UPLC-Q/TOF-MS and network pharmacology.
- To evaluate the therapeutic potential of Swertianin for MASLD.
- To elucidate Swertianin's mechanism involving PPARG activation and macrophage modulation.
Main Methods:
- Utilized UPLC-Q/TOF-MS and network pharmacology to identify key compounds and targets of Swertia davidi Franch.
- Conducted in vitro macrophage experiments to assess M1 polarization modulation.
- Employed a mouse model of MASLD to evaluate Swertianin's therapeutic efficacy.
Main Results:
- Swertianin activated PPARG, significantly inhibiting M1 macrophage polarization.
- Observed reduced lipid accumulation and decreased inflammatory markers in vitro and in vivo.
- Demonstrated significant improvement in liver pathology in MASLD mouse models.
Conclusions:
- Swertianin activates PPARG, offering a novel therapeutic mechanism for MASLD.
- The study highlights Swertianin's potential to target macrophage polarization and inflammation in MASLD.
- Swertianin shows promise as a treatment for MASLD by modulating key inflammatory pathways.
